Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Eric, Nuermberger"'
Autor:
Ahmed A. Abulfathi, Veronique de Jager, Elana van Brakel, Helmuth Reuter, Nikhil Gupte, Naadira Vanker, Grace L. Barnes, Eric Nuermberger, Susan E. Dorman, Andreas H. Diacon, Kelly E. Dooley, Elin M. Svensson
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Meropenem is being investigated for repurposing as an anti-tuberculosis drug. This study aimed to develop a meropenem population pharmacokinetics model in patients with pulmonary tuberculosis and identify covariates explaining inter-indiv
Externí odkaz:
https://doaj.org/article/cadb0a5433cf4817a6465fe5572efa83
Autor:
Jian Xu, Dongshuo Li, Jinghua Shi, Bin Wang, Fei Ge, Zhenyong Guo, Xiaopan Mu, Eric Nuermberger, Yu Lu
Publikováno v:
Antimicrobial Agents and Chemotherapy.
Bedaquiline (BDQ) is an effective drug for the treatment of drug-resistant tuberculosis. Mutations in atpE , which encodes the target of BDQ, are associated with large increases in MICs. Mutations in Rv0678 that derepress the transcription of the Mmp
Autor:
Kristal A. Rychlik, Emily J. Illingworth, Ian F. Sanchez, Sarah E. Attreed, Prithvi Sinha, Kevin M. Casin, Nicole Taube, Jeff Loube, Rokeya Tasneen, Raihan Kabir, Eric Nuermberger, Wayne Mitzner, Mark J. Kohr, Fenna C.M. Sillé
Publikováno v:
Toxicology Letters.
Autor:
Axel Treu, Christoph Hölscher, Julia Kokesch-Himmelreich, Franziska Marwitz, Julia Dreisbach, Paul Converse, Sandeep Tyagi, Sina Gerbach, Luzia Gyr, Ann-Kathrin Lemm, Johanna Volz, Alexandra Hölscher, Norbert Heinrich, Florian Kloss, Eric Nuermberger, Dominik Schwudke, Michael Hoelscher, Andreas Römpp, Kerstin Walter
Centrally necrotizing granulomas that harbor Mycobacterium tuberculosis (Mtb) are the hallmark of human tuberculosis (TB). New anti-TB therapies will need to effectively penetrate the cellular and necrotic, non-vascularized compartments of these lesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ec4e19a6c95771b30645d0728ad9557
https://doi.org/10.21203/rs.3.rs-2615777/v1
https://doi.org/10.21203/rs.3.rs-2615777/v1
Despite known treatments, tuberculosis (TB) remains the world’s top infectious killer, highlighting the pressing need for new drug regimens. To prioritize the most efficacious drugs for clinical testing, we previously developed a PK-PD translationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96f9906076938170fbb134d621318cae
https://doi.org/10.1101/2023.02.16.528876
https://doi.org/10.1101/2023.02.16.528876
Autor:
Jacqueline P. Ernest, Janice Jia Ni Goh, Natasha Strydom, Qianwen Wang, Rob C. van Wijk, Nan Zhang, Amelia Deitchman, Eric Nuermberger, Rada M. Savic
Publikováno v:
bioRxiv
BackgroundPhase 2a trials in tuberculosis typically use early bactericidal activity (EBA), the decline in sputum colony forming units (CFU) over 14 days, as the primary outcome for testing the efficacy of drugs as monotherapy. However, the cost of ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a464ad23ca0131b403c0e761628b36f
https://europepmc.org/articles/PMC9882354/
https://europepmc.org/articles/PMC9882354/
Autor:
Stéphane Leung-Theung-Long, Charles-Antoine Coupet, Marie Gouanvic, Doris Schmitt, Aurélie Ray, Chantal Hoffmann, Huguette Schultz, Sandeep Tyagi, Heena Soni, Paul J Converse, Lilibeth Arias, Patricia Kleinpeter, Benoît Sansas, Khisimuzi Mdluli, Cristina Vilaplana, Pere-Joan Cardona, Eric Nuermberger, Jean-Baptiste Marchand, Nathalie Silvestre, Geneviève Inchauspé
Publikováno v:
PLoS ONE, Vol 13, Iss 5, p e0196815 (2018)
Despite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strain
Externí odkaz:
https://doaj.org/article/2492b61a9de840cdb94a05e96383a78d
Autor:
Emily A Kendall, Sourya Shrestha, Ted Cohen, Eric Nuermberger, Kelly E Dooley, Lice Gonzalez-Angulo, Gavin J Churchyard, Payam Nahid, Michael L Rich, Cathy Bansbach, Thomas Forissier, Christian Lienhardt, David W Dowdy
Publikováno v:
PLoS Medicine, Vol 14, Iss 1, p e1002202 (2017)
BACKGROUND:Novel drug regimens are needed for tuberculosis (TB) treatment. New regimens aim to improve on characteristics such as duration, efficacy, and safety profile, but no single regimen is likely to be ideal in all respects. By linking these re
Externí odkaz:
https://doaj.org/article/2c499268a7474e30bdf8c3ab113b4ff3
Autor:
Grania Brigden, Bern-Thomas Nyang'wa, Philipp du Cros, Francis Varaine, Jennifer Hughes, Michael Rich, C Robert Horsburgh Jr, Carole D Mitnick, Eric Nuermberger, Helen McIlleron, Patrick PJ Phillips, Manica Balasegaram
Publikováno v:
Bulletin of the World Health Organization, Vol 92, Iss 1, Pp 68-74 (2014)
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers to scale-up is the treatment regimen, which is lengthy, complex,
Externí odkaz:
https://doaj.org/article/3a141876b7684af6b2d26b55feec2b66
Autor:
Jidong Zhang, Christine Lair, Christine Roubert, Kwame Amaning, María Belén Barrio, Yannick Benedetti, Zhicheng Cui, Zhongliang Xing, Xiaojun Li, Scott G. Franzblau, Nicolas Baurin, Florence Bordon-Pallier, Cathy Cantalloube, Stephanie Sans, Sandra Silve, Isabelle Blanc, Laurent Fraisse, Alexey Rak, Lasse B. Jenner, Gulnara Yusupova, Marat Yusupov, Junjie Zhang, Takushi Kaneko, T.J. Yang, Nader Fotouhi, Eric Nuermberger, Sandeep Tyagi, Fabrice Betoudji, Anna Upton, James C. Sacchettini, Sophie Lagrange
Publikováno v:
Cell. 186:1013-1025.e24